1. Home
  2. TC vs NSRX Comparison

TC vs NSRX Comparison

Compare TC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TuanChe Limited

TC

TuanChe Limited

N/A

Current Price

$9.73

Market Cap

29.0M

ML Signal

N/A

NSRX

Nasus Pharma Ltd. Ordinary Shares

SELL

Current Price

$2.91

Market Cap

25.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
TC
NSRX
Founded
2010
2019
Country
China
Israel
Employees
N/A
7
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.0M
25.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TC
NSRX
Price
$9.73
$2.91
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$19.67
AVG Volume (30 Days)
620.0
101.7K
Earning Date
03-28-2025
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$1.98
52 Week High
$19.99
$9.99

Technical Indicators

Market Signals
Indicator
TC
NSRX
Relative Strength Index (RSI) 31.49 48.51
Support Level $8.93 $2.04
Resistance Level $11.10 $5.20
Average True Range (ATR) 0.25 0.40
MACD -0.03 0.17
Stochastic Oscillator 2.32 33.89

Price Performance

Historical Comparison
TC
NSRX

About TC TuanChe Limited

Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: